1025-P: Success of Interactive, Online Education Related to Screening and Staging Type 1 Diabetes

Abstract

Objective: Determine if interactive, case-based, online continuing medical education (CME) improves the competence and confidence of diabetologists/endocrinologists (D/Es) and pediatricians on staging T1D. Methods: Educational design included a “test, then teach” approach to elicit cognitive dissonance, with evidence-based feedback provided following each learner response. A repeated pairs pre-/post-assessment study design and a McNemar’s test (P <.05 is considered significant) assessed educational effect, with Cohen’s d being used to assess educational impact (<0.2 modest effect, 0.2-0.49 small effect, 0.5-0.79 moderate effect and >0.8 extensive effect). The activity launched July 29, 2022 and data were collected through October 6, 2022. Results: 77 D/Es and 160 pediatricians were included in the analysis. Matched learner data indicate that overall, 77% D/Es and 76% of pediatricians improved their competence from pre-to-post (both P<.0001 with extensive overall impacts in both groups 0.9-1.06) On a question-level: 56% of D/Es (P<.001) and 48% of pediatricians (P<.001) improved at appropriate screening of high-risk patients for T1D 27% of D/Es (P<.001) and 31% of pediatricians (P<.001) improved at educating caregivers about screening of siblings at risk of T1D 51% of D/Es (P<.001) and 51% of pediatricians (P<.001) improved at staging of patients with T1D based on test results Overall, 60% of D/Es and 61% of pediatricians reported increased confidence in staging patients with T1D, for an overall confidence shift of +75% in D/Es and +96% in pediatricians with increased confidence. Conclusion: Interactive, case-based, online CME is successful at improving competence and confidence of D/Es and pediatricians related to staging of at-risk patients for T1D. Case-based education with interactive polling questions and detailed explanations related to best choices should be employed more often to help clinicians apply guidelines into practice to improve patient care. Disclosure A.Larkin: None. A.Le: None. Funding Provention Bio, Inc.